NEW YORK, April 18 (GenomeWeb News) - RNAi reagent provider Dharmacon said today that it has signed a deal under which it will provide its siRNA libraries to Cancer Research UK for use in drug discovery and development.
According to Dharmacon, the libraries will initially include protein kinase genes and associated pathways. They will be used by Cancer Research
If this research is successful, Cancer Research
Specific terms of the arrangement were not disclosed.